Skip to main content

Table 1 Demographics and clinical characteristics of patients

From: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

Characteristic cohort (n = 54) Training cohort (n = 106)
No. (%)
Validation
No. (%)
p
Age, y
 Median (range) 47(24–73) 43(19–78) 0.9718
Sex
 Female 29 (27.36) 18 (33.33) 0.4660
 Male 77 (72.64) 36 (66.67)
Recurrence
 Yes 50 (47.17) 23 (42.59) 0.6180
 No 56(52.83) 31 (57.41)
ECOG
 0 6 (5.66) 9 (16.67) 0.1930
 1 98 (92.45) 45 (83.33)
 2 2 (1.89) 0 (0.00)
Histological type
 Poorly differentiated type 3 (2.83) 6 (11.11) 0.0620
 Undifferentiated type 103 (97.17) 48 (88.89)
Clinical stage
 II–III 38 (35.85) 19 (35.19) 0.1430
 IVa 21 (19.81) 15 (27.78)
 IVb 36(33.96) 12 (22.22)
 IVc 11 (10.38) 8 (14.81)
Tumor stage
 T0–2 24 (22.64) 12 (22.22) 0.9520
 T3–4 82 (77.36) 42 (77.78)
Node stage
 N0–1 47 (44.34) 23 (42.59) 0.8670
 N2–3 59 (55.66) 31 (57.41)
Metastasis stage
 M0 49 (46.23) 28 (51.85) 0.5090
 M1 57 (53.77) 26(48.15)
Outcomes
 PR 24 (22.64) 10 (18.52) 0.0610
 SD 68 (64.15) 35 (64.81)
 PD 14 (13.21) 9 (16.67)
The PD1 drug
 Camrelizumab 16 (15.09) 2 (3.70) 0.2070
 Pembrolizumab 3 (2.83) 0 (0.00)
 Toripalimab 72 (67.93) 45 (83.33)
 Sintilimab 15 (14.15) 7 (12.97)
  1. ECOG Eastern Cooperative Oncology Group Performance Status, PR partial response, SD stable disease; PD progressive disease